(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.45%) $78.03
(0.14%) $2.21
(0.03%) $2 324.90
(0.08%) $27.57
(-0.15%) $986.90
(0.15%) $0.931
(0.39%) $10.94
(0.16%) $0.801
(-0.02%) $91.42
5 days till quarter result
(tns 2024-05-13)
Expected move: +/- 14.88%
@ $3.52
Issued: 8 Feb 2024 @ 14:59
Return: -12.78%
Previous signal: Feb 7 - 15:44
Previous signal:
Return: 2.03 %
Live Chart Being Loaded With Signals
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers...
Stats | |
---|---|
Today's Volume | 206 994 |
Average Volume | 309 159 |
Market Cap | 117.47M |
EPS | $0 ( 2024-03-22 ) |
Next earnings date | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.770 |
ATR14 | $0.0110 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Gilead Sciences, Inc. | Sell | 0 | Common Stock |
2024-01-29 | Mashiach Nissim | Buy | 25 000 | Stock Option (Right to Buy) |
2024-01-29 | Dietz Thomas John | Buy | 30 000 | Stock Option (Right to Buy) |
2024-01-29 | Schilsky Richard | Buy | 25 000 | Stock Option (Right to Buy) |
2024-01-29 | Granfield Christine | Buy | 85 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
66.48 |
Last 95 transactions |
Buy: 10 825 606 | Sell: 1 768 106 |
Volume Correlation
Leap Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
LPCN | 0.922 |
EWTX | 0.919 |
CNDT | 0.917 |
SRAX | 0.915 |
CPIX | 0.911 |
NESR | 0.909 |
RPAY | 0.905 |
VTRS | 0.903 |
HNNA | 0.9 |
SMSI | 0.899 |
10 Most Negative Correlations | |
---|---|
CNCE | -0.851 |
CNST | -0.84 |
TYHT | -0.838 |
UNCY | -0.828 |
ALR | -0.821 |
EPZM | -0.819 |
PSACU | -0.817 |
BTBD | -0.811 |
VERX | -0.81 |
DRNA | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Leap Therapeutics Inc Correlation - Currency/Commodity
Leap Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-427 000 (0.00 %) |
EPS: | $-3.98 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-427 000 (0.00 %) |
EPS: | $-3.98 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-415 000 (0.00 %) |
EPS: | $-4.82 |
FY | 2021 |
Revenue: | $1.50M |
Gross Profit: | $1.50M (100.00 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Leap Therapeutics Inc
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators